Pfizer announces approval of Ibrance is getting closer

A targeted therapy for HER2 negative breast cancer is going to be introduced in Korea.

According to the industry concerned on the 16^th, a Pfizer Pharmaceuticals Korea’s new breast cancer therapy, ‘Ibrance(palbociclib),’ is expected to acquire approval in the second half of the year.

Generally, the progress of hormone receptor positive breast cancer gets affected by CDK4 and CDK6, but Ibranc...